452 related articles for article (PubMed ID: 30503325)
1. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
Phillips AN; Venter F; Havlir D; Pozniak A; Kuritzkes D; Wensing A; Lundgren JD; De Luca A; Pillay D; Mellors J; Cambiano V; Bansi-Matharu L; Nakagawa F; Kalua T; Jahn A; Apollo T; Mugurungi O; Clayden P; Gupta RK; Barnabas R; Revill P; Cohn J; Bertagnolio S; Calmy A
Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
[TBL] [Abstract][Full Text] [Related]
2. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
[TBL] [Abstract][Full Text] [Related]
4. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
[TBL] [Abstract][Full Text] [Related]
6. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
[TBL] [Abstract][Full Text] [Related]
7. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
[TBL] [Abstract][Full Text] [Related]
8. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
[TBL] [Abstract][Full Text] [Related]
9. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol.
Semengue ENJ; Santoro MM; Ndze VN; Dambaya B; Takou D; Teto G; Nka AD; Fabeni L; Wiyeh A; Ceccherini-Silberstein F; Colizzi V; Perno CF; Fokam J
Syst Rev; 2020 Apr; 9(1):93. PubMed ID: 32334643
[TBL] [Abstract][Full Text] [Related]
11. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
[TBL] [Abstract][Full Text] [Related]
12. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir.
Meireles MV; Pascom ARP; Duarte EC; McFarland W
AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860
[TBL] [Abstract][Full Text] [Related]
14. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
15. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
16. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.
Zheng A; Kumarasamy N; Huang M; Paltiel AD; Mayer KH; Rewari BB; Walensky RP; Freedberg KA
J Int AIDS Soc; 2018 Mar; 21(3):e25085. PubMed ID: 29603882
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
19. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
Derache A; Iwuji CC; Danaviah S; Giandhari J; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Pillay D; Gupta RK
J Antimicrob Chemother; 2019 Feb; 74(2):473-479. PubMed ID: 30380053
[TBL] [Abstract][Full Text] [Related]
20. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
